Stir bar-sorptive extraction, solid phase extraction and liquid-liquid extraction for levetiracetam determination in human plasma: comparing recovery rates / Extração sortiva em barra de agitação, extracção da fase sólida e de extracção líquido-líquido para a determinação de levetiracetam em plasma humano: comparando as taxas de recuperação

Levetiracetam (LEV), an antiepileptic drug (AED) with favorable pharmacokinetic profile, is increasingly being used in clinical practice, although information on its metabolism and disposition are still being generated. Therefore a simple, robust and fast liquid-liquid extraction (LLE) followed by high-performance liquid chromatography method is described that could be used for both pharmacokinetic and therapeutic drug monitoring (TDM) purposes. Moreover, recovery rates of LEV in plasma were compared among LLE, stir bar-sorptive extraction (SBSE), and solid-phase extraction (SPE). Solvent extraction with dichloromethane yielded a plasma residue free from usual interferences such as commonly co-prescribed AEDs, and recoveries around 90% (LLE), 60% (SPE) and 10% (SBSE). Separation was obtained using reverse phase Select B column with ultraviolet detection (235 nm). Mobile phase consisted of methanol:sodium acetate buffer 0.125 M pH 4.4 (20:80, v/v). The method was linear over a range of 2.8-220.0 µg mL^-1. The intra- and inter-assay precision and accuracy were studied at three concentrations; relative standard deviation was less than 10%. The limit of quantification was 2.8 µg mL^-1. This robust method was successfully applied to analyze plasma samples from patients with epilepsy and therefore might be used for pharmacokinetic and TDM purposes...

Levetiracetam, fármaco antiepiléptico com perfil farmacocinético favorável, tem sido cada vez mais utilizado na prática clínica, embora informações sobre seu metabolismo e disposição cinética ainda estejam sendo geradas. Um método simples, robusto e rápido de extração líquido-líquido seguido por análise por cromatografia líquida de alta eficiência é aqui descrito para servir tanto a investigações farmacocinéticas quanto à monitorização terapêutica. Além disso, as taxas de recuperação do levetiracetam em plasma foram comparadas entre a extração líquido-líquido, a extração sortiva em barra de agitação e a extração em fase sólida. Extração com o solvente diclorometano resultou em plasma livre de interferentes, tais como fármacos antiepilépticos co-prescritos, e apresentou taxas de recuperação em torno de 90% (extração líquido-líquido), 60% (extração em fase sólida) e 10% (extração sortiva em barra de agitação). A separação foi obtida utilizando-se coluna de fase reversa Select B e detecção ultravioleta (235 nm). A fase móvel foi composta por metanol:tampão acetato de sódio 0,125 M pH 4,4 (20:80, v/v). O método mostrou-se linear para o intervalo de 2,8 a 220,0 µg mL^-1. Precisão intra- e interdias e a exatidão foram avaliadas em três concentrações; o desvio padrão relativo foi inferior a 10%. O limite de quantificação foi 2.8 µg mL^-1. Este método foi aplicado para análise de amostras de plasma de pacientes com epilepsia e, desta forma, pode ser utilizado satisfatoriamente tanto para fins de farmacocinética quanto de monitorização terapêutica...

Tratamiento con medicamentos antiepilépticos en el niño / Antiepileptic drug treatment for children

El objetivo de este trabajo es realizar una revisión de la literatura sobre el tratamiento con medicamentos antiepilépticos en el niño. Un aspecto importante en el tratamiento de la epilepsia es disminuir o lograr la cesación de las crisis epilépticas para garantizar una calidad de vida adecuada. Existen varios factores que se deben considerar en el momento de seleccionar el primer medicamento antiepiléptico, entre los se encuentran la eficacia relativa, la tolerabilidad, las interacciones medicamentosas y seguridad a largo plazo del fármaco seleccionado, el tipo de crisis epiléptica, el síndrome epiléptico, la edad, el sexo, el peso, las comorbilidades asociadas, entre otros. Si se decide emplear tratamiento adjunto, deben combinarse medicamentos con diferentes mecanismos de acción. Todos los antiepilépticos clásicos o de primera generación son medicamentos eficaces que continúan desempeñando un papel importante en el tratamiento actual de la epilepsia. Estos fármacos en la actualidad se emplean en el tratamiento de primera opción para muchos tipos de crisis epilépticas o síndromes epilépticos. Son pocos los medicamentos antiepilépticos de segunda generación que en la actualidad se consideran de primera elección para el tratamiento de la epilepsia en el niño

The objective of this paper was to make a literature review on the antiepileptic drug treatment for children. An important aspect of this type of treatment is to reduce or to cease epileptic crises in order to assure better quality of life. There are several factors that should be considered at the time of selecting the first antiepileptic drug such as relative efficacy, tolerability, drug interactions and long-term safety of the selected drug, type of seizure, epileptic syndrome, age, sex, weight, associated comorbidities and others. If one decides to use a combined treatment, then drugs having various mechanisms of action must be selected. The first-generation or classical antiepileptic drugs are all effective and continue playing an important role in the present treatment of epilepsy. These drugs are currently used as treatment of choice for many types of seizures or epileptic syndromes. Few second generation antiepileptic drugs are considered at present to be the first choice for the treatment of epilepsy in the child

Epilepsy treatment: a paradigm shift is urgently need / Tratamento da epilepsia: uma mudança de paradigma é urgentemente necessária

Epilepsy affects between 5 and 10 people in a 1,000 and carries considerable morbidity and premature mortality. The complex inheritance pattern of a lowered seizure threshold is not fully understood but is likely to be polygenic. In the majority of people with epilepsy, we do not understand the pathophysiology, how a seizure is triggered, and how it can be prevented. In the centennial year of the discovery of the antiepileptic properties of phenobarbital, we have over 20 antiepileptic drugs; however, none have dramatically changed the long-term prognosis of the condition. The cascade of events triggering epilepsy is likely to vary greatly among individuals. The hope for the future is a shift of paradigm away from the symptomatic approach that currently exists. Indeed, once epileptogenesis is fully understood, treatment can be targeted at specific mechanisms, and then we will have truly disease-modifying therapies.

A epilepsia afeta entre 5 e 10 em cada 1.000 pessoas, e está associada a comorbidades e mortalidade prematura. O complexo padrão de herança, possivelmente poligênico, para baixo limiar convulsivo, ainda não é bem compreendido. Na maioria das pessoas com epilepsia ainda não entendemos a sua fisiopatologia, como as crises epilépticas são desencadeadas ou como podem ser prevenidas. No centenário da descoberta das propriedades antiepilépticas do fenobarbital, temos mais de 20 drogas disponíveis para tratamento de epilepsia; contudo, nenhum fármaco mudou dramaticamente o prognóstico desta condição, em longo prazo. A cascata de eventos que desencadeia a epilepsia, provavelmente, varia muito de indivíduo para indivíduo. A esperança para o futuro é a mudança do atual paradigma da abordagem sintomática. Uma vez que a epileptogênese seja melhor compreendida, o tratamento poderá ser direcionado aos seus mecanismos específicos e então poderemos dispor de tratamentos capazes de modificar a história natural da doença.

Consenso chileno de manejo de fármacos antiepilépticos en algunos síndromes electro-clínicos y otras epilepsias en niños y adolescentes / Chilean consensus on the use of antiepileptic drugs in electro-clinical syndromes

Por iniciativa de tres instituciones: Liga Chilena contra la Epilepsia (LICHE), Sociedad de Epileptología de Chile (SOCEPCHI) y Sociedad de Psiquiatría y Neurología de la Infancia y Adolescencia (SOPNIA) de Chile, se constituye un comité de trabajo que convoca a un consenso de uso de fármacos antiepilépticos (FAEs) en un grupo de 16 Síndromes electro-clínicos y otras Epilepsias en niños y adolescentes. Cuarenta y dos médicos neuropediatras especialistas en Epilepsias de todas las regiones de Chile, participaron en la discusión y realizaron una propuesta de tratamiento farmacológico para cada cuadro. El comité de trabajo realizó un análisis exhaustivo y discusión de los documentos, para finalmente concluir en una recomendación de tratamiento para cada cuadro. Este consenso es una guía práctica de orientación para ayudar a las decisiones de tratamiento en situaciones clínicas concretas. Su objetivo final es ofrecer una mejor calidad de atención a los niños y adolescentes con epilepsias, a través de decisiones fundadas que contribuyan a disminuir la variabilidad de las decisiones terapéuticas.

Committed by three institutions: Liga Chilena contra la Epilepsia (LICHE), Sociedad de Epileptología de Chile (SOCEPCHI) y Sociedad de Psiquiatría y Neurología de la Infancia y Adolescencia (SOPNIA) de Chile, a 6-member working committee called for a meeting of 42 Chilean pediatric epileptologists from all over the country, with the aim of reaching a consensus on the use of antiepileptic drugs in 16 selected children and adolescents electro-clinical syndromes and epilepsies. These treatment proposals were analyzed and fully discussed by the working committee, ending in an antiepileptic drug treatment recommendation guideline for each condition. This consensus is a practical guideline to be used in specific clinical situations, which aims to support treatment decision making. Its main purpose is to offer the best evidence based treatments to our children and adolescents patients with epilepsy, thus contributing to diminish variability in therapeutic decisions.

The Pharmacotherapy of Childhood Epilepsy / 소아과

Epilepsy is one of the most common and disabling neurologic disorders in childhood. The primary goal of epilepsy treatment is to choose the treatment modality that provides the best chance of improving the patient's quality of life. In addition to classic antiepileptic drugs, newly developed antiepileptic drugs ketogenic diet, epilepsy surgery, and vagal nerve stimulation have improved the ability to treat seizure disorders during the past decades. The mainstay of treatment remains pharmacotherapy. The factors that affect decision of whether to treat seizures with medications and which antiepileptic drugs to use include the likelihood of seizure recurrence, type and severity of seizures, available antiepileptic drug efficacies and toxicities, need for hematologic monitoring, ease to dosing, underlying illness, pharmacologic interaction, and school and other social issues. In this article, we will describe the principle of drug selection for seizure disorder in pediatric patients and the efficacies and adverse effects of the typical and new antiepileptics. Information about the available antiepileptic drugs will help the pediatrician to select the best drug for children with epilepsy.

Clinical study of compound Qianglizhenxian pill on epilepsy / 中国康复理论与实践

@#Objective To investigate the clinical effect of compound Qianglizhenxian pill on epilepsy. Methods 94 patients with epilepsy were treated with compound Qianglizhenxian pill, and every course lasted three months. After treatment, checking patients' electroencephalogram again, evaluating the clinical effect according to degrees and numbers of attack. Results After 12 months of treatment, 90.43% of patients got an obvious improvement, while 6.38% for better, 3.19% for validity and no invalid. Conclusions There is a great improvement for patients with epilepsy after taking the medicine. The effective control rate is 92.62% with no toxication on blood system, liver and kidney.